Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • ALK
    (3)
  • Akt
    (2)
  • Apoptosis
    (7)
  • CDK
    (3)
  • FAK
    (25)
  • IGF-1R
    (2)
  • PROTACs
    (2)
  • PYK2
    (5)
  • Src
    (2)
  • Others
    (10)
Filter
Search Result
Results for "

Focal adhesion kinase

" in TargetMol Product Catalog
  • Inhibitor Products
    34
    TargetMol | Activity
  • Recombinant Protein
    4
    TargetMol | inventory
  • PROTAC Products
    3
    TargetMol | natural
  • Natural Products
    3
    TargetMol | composition
  • Peptides Products
    1
    TargetMol | Activity
Roslin 2 bromide
T2473029574-21-8In house
Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5. Roslin 2 bromide exhibits anticancer effects.
  • $44
In Stock
Size
QTY
PF-573228
T2001869288-64-2
PF-573228 is an ATP-competitive FAK inhibitor. In a cell-free assay, the IC50 of FAK is 4 nM.
  • $45
In Stock
Size
QTY
TargetMol | Citations Cited
PF-431396
T2314717906-29-1
PF-431396 is a dual PYK2/FAK inhibitor (IC50: 11/2 nM).
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
GSK2256098
T22811224887-10-8
GSK2256098 (GTPL7939) is a small molecule FAK kinase inhibitor.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
NVP-TAE 226
T1918761437-28-9
NVP-TAE 226 (TAE226) is an effective FAK inhibitor (IC50: 5.5 nM) and most effective to Pyk2(IC50: 3.5 nM); 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and ALK.
  • $41
In Stock
Size
QTY
TargetMol | Citations Cited
Y15
T71194506-66-5
Y15 (1,2,4,5-Benzenetetramine tetrahydrochlor) is a potent and specificsmall-molecule FAK scaffolding inhibitor that inhibits its autophosphorylation activity, blocks tumor growth.
  • $43
In Stock
Size
QTY
TargetMol | Citations Cited
Defactinib
T19961073154-85-4
Defactinib (VS-6063) is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
PF-562271
T2465717907-75-0
PF-562271 is an effective ATP-competitive, reversible inhibitor of FAK(IC50=1.5 nM) and Pyk2 kinase(IC50=13 nM).
  • $54
In Stock
Size
QTY
TargetMol | Citations Cited
FAK-IN-7
T997319948-85-7
FAK-IN-7 has potential antiproliferative activity and is a FAK inhibitor.
  • $33
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PROTAC FAK degrader 1
T138402301916-69-6
PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).
  • $456
Backorder
Size
QTY
TargetMol | Inhibitor Sale
CEP-37440
T26551391712-60-9
CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
  • $31
In Stock
Size
QTY
ALK inhibitor 1
T10285761436-81-1
ALK inhibitor 1 is a selective ALK kinase inhibitor.
  • $80
In Stock
Size
QTY
Masitinib
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
  • $31
In Stock
Size
QTY
PF-562271 hydrochloride
T21768939791-41-0
PF-562271 hydrochloride (PF-562271 HCl) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
  • $71
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Chloropyramine hydrochloride
T02636170-42-9
Chloropyramine hydrochloride (Alergosan) is a histamine receptor H1 antagonist.
  • $33
In Stock
Size
QTY
Nitidine chloride
T5S076113063-04-2
1. Nitidine chloride has inhibitory effects on various tumors, such as renal cancer , breast cancer. 2. Nitidine chloride inhibits the proliferation of SMMC-7721 cells in vitro in a time- and dose-dependent manner and identifies efficacy in vivo in a mouse model of HCC.
  • $30
In Stock
Size
QTY
GSK215
T678432743427-26-9
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader (pDC50= 8.4). GSK215 is designed by the FAK inhibitor VS-4718 and a binder for the VHL E3 ligase. GSK215 can induce rapid and prolonged FAK degradation.
  • $127
In Stock
Size
QTY
Azurin (50-77) (P. aeruginosa) TFA
T83680
Azurin (50-77) is a peptide fragment derived from the copper-containing bacterial protein azurin, present in P. aeruginosa. It exhibits properties that regulate the cell cycle, inhibit cancer proliferation, and manage angiogenesis, proving its potential as an anticancer agent. Specifically, this compound acts as a VEGFR2 inhibitor with an IC20 of approximately 10.7 µM. At a concentration of 20 µM, it effectively induces cell cycle arrest at the G2/M phase in MCF-7 breast cancer cells, while a higher concentration of 50 µM significantly reduces the proliferation of both MCF-7 and ZR-75-1 breast cancer cell lines. Furthermore, Azurin (50-77) impedes VEGF-A-induced capillary tube formation with an IC50 of 12 µM, and alters the cellular and extracellular levels of critical signaling and structural proteins such as F-actin, focal adhesion kinase (FAK), paxillin, and platelet endothelial cell adhesion molecule-1 (PECAM-1) in human umbilical vein endothelial cells (HUVECs) at a concentration of 25 µM. Demonstrating its efficacy in vivo, Azurin (50-77) administered at 10 mg/kg per day notably reduces tumor volume in an MCF-7 mouse xenograft model, highlighting its therapeutic potential.
  • $63
Backorder
Size
QTY
PND-1186
T19501061353-68-1
PND-1186 (VS-4718) is a reversible and specific FAK inhibitor (IC50: 1.5 nM).
  • $48
In Stock
Size
QTY
Fangchinoline
T3122436-77-1
Fangchinoline (Tetrandrine B) is extracted from Stephania tetrandra S. Moore.
  • $43
In Stock
Size
QTY
GSK-2256098 HCl
T707241416771-10-2
GSK-2256098 HCl is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
  • $1,520
1-2 weeks
Size
QTY
OXA-11
T282771257994-15-2
OXA-11 is a potent inhibitor of focal adhesion kinase (FAK) with anti-tumor activity.
  • $2,870
10-14 weeks
Size
QTY
PF-4618433
T223971166393-85-6
PF-4618433 is a dual inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2).
  • $196
5 days
Size
QTY
NVP-TAC544
T68740761436-62-8
NVP-TAC544 is a novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R.
  • $1,520
6-8 weeks
Size
QTY
VSWRAPTA
T350752229829-30-3
VSWRAPTA is a promoter of neuronal branching via transcellular activation of the focal adhesion kinase (FAK) and the ERK1/2 signaling pathway in vitro.
  • $1,520
Backorder
Size
QTY
FAK inhibitor 2
T112602354405-14-2
FAK inhibitor 2, antitumor and anti-angiogenesis activitiesis ,is a potent focal adhesion kinase (FAK) inhibitor with an IC50 of 0.07 nM .
  • $1,230
6-8 weeks
Size
QTY
Y 11
T235391086639-59-9
focal adhesion kinase (FAK) inhibitor
  • $110
35 days
Size
QTY
ALK inhibitor 2
T3041761438-38-4
ALK inhibitor 2 is a new-type and selective inhibitor for the ALK kinase.
  • $118
In Stock
Size
QTY
PH11
T703521627843-95-1
PH11 is a novel Focal Adhesion Kinase (FAK) inhibitor. PH11 restores TRAIL apoptotic pathway in PANC-1 cells through down-regulation of c-FLIP via inhibition of FAK and the phosphatidylinositol-3 kinase (PI3K)/AKT pathways. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) emerges as one of the most-promising experimental cancer therapeutic drugs and is currently being tested in clinical trials. However, both intrinsic and acquired resistance of human cancer cells to TRAIL-induced apoptosis poses a huge problem in establishing clinically efficient TRAIL therapies.
  • $1,520
6-8 weeks
Size
QTY
AMP-945
T95761393653-34-3
AMP-945 is a proprietary focal adhesion kinase (FAK) inhibitor.
  • $98
In Stock
Size
QTY
BI-4464
T54801227948-02-8
BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC
  • $52
In Stock
Size
QTY
PF-562271 besylate
T6177939791-38-5
PF-562271 besylate (PF-00562271 Besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
  • $53
In Stock
Size
QTY
Batatasin III
TN143356684-87-8
Batatasin III inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition and FAK-AKT signals and possesses anti-cancer activities. Batatasin III has a long-term inhibitory effect on whole-plant growth and shows germination
  • $107
In Stock
Size
QTY
SU6656
T6997330161-87-0
SU 6656 is a selective inhibitor of Src family kinases, with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
  • $34
In Stock
Size
QTY